Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy presents a rigorous examination of advanced strategies for the selective targeting of neoplastic cells and their distinct microenvironments. This comprehensive volume elucidates both tissue-specific and tumor-specific molecular targets, clarifying how these methodologies can significantly enhance therapeutic precision while mitigating off-target effects. The initial section of the text provides an in-depth analysis of tissue-specific regulatory targets across various organs, including the liver, lungs, brain, skin, and bones. It delineates the critical mediators and mechanisms that govern tumor immunity, thereby identifying novel therapeutic avenues.
Each chapter meticulously evaluates key regulatory molecules such as TGF-?, CTLA-4, and IL-10, exploring their roles in tumorigenesis and the potential for targeted interventions across a spectrum of malignancies. Subsequent sections focus on tumor tissue-specific molecular targets, encompassing immunological checkpoints, growth factors, and signaling pathways pertinent to cancers of the liver, stomach, ovary, prostate, and colon. The text provides insights into the application of monoclonal antibodies and molecular inhibitors as strategies to impede cancer progression and address therapeutic resistance. Concluding chapters address emerging therapeutic paradigms, including precision medicine and nanotechnology.
Each chapter meticulously evaluates key regulatory molecules such as TGF-?, CTLA-4, and IL-10, exploring their roles in tumorigenesis and the potential for targeted interventions across a spectrum of malignancies. Subsequent sections focus on tumor tissue-specific molecular targets, encompassing immunological checkpoints, growth factors, and signaling pathways pertinent to cancers of the liver, stomach, ovary, prostate, and colon. The text provides insights into the application of monoclonal antibodies and molecular inhibitors as strategies to impede cancer progression and address therapeutic resistance. Concluding chapters address emerging therapeutic paradigms, including precision medicine and nanotechnology.
Table of Contents
Part I. Tissue-Specific Targets1. Brain-Specific Regulatory T Cell (Treg) Mediators
2. Liver-Specific Regulatory T Cell Mediators
3. Lung-Specific Regulatory T Cell Mediators
4. Adrenal Gland-Specific Regulatory T Cell Mediators
5. Lymph Node-Specific Regulatory T Cell Mediators
6. Skin-Specific Regulatory T Cell Mediators
7. Bone-Specific Regulatory T Cell Mediators
8. Colon-Specific Regulatory T Cell Mediators
9. Breast-Specific Regulatory T Cell Mediators
Part II. Tumor Tissue-Specific Targets
10. Molecular Targets for Liver Cancer
11. Molecular Targets for Gastric Cancer
12. Molecular Targets for Breast Cancer
13. Molecular Targets for Ovarian Cancer
14. Molecular Targets in Prostate Cancer
15. Molecular Targets in Colon Cancer
16. Molecular Targets in Lung Cancer
17. Molecular Targets in Blood Cancer
Part III. Advanced Therapeutic Approaches
18. Human Genetic Mutation-Based Targeting
19. Microbiome in Cancer Immunotherapy and Cancer Progression
20. Precision Medicine
21. Future Directions and Challenges in Cancer Targeting Therapies
Authors
Lalit Kumar Assistant Professor, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dalapathi Gugulothu Delhi Institute of Pharmaceutical Sciences and Research, India.Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi.
Sushama Talegaonkar Associate Professor, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India. Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled "Development and bioavailability assessment of ramipril nanoemulsion formulation� has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010-11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.
